SPAC Presentation

Proprietary Portfolio of Branded Rx and OTC Products Robust Proprietary Portfolio with Strong Growth Rates Portfolio Growth Benchmark¹ (Region) Market Procaps 5% 7% 2018 5% 16% 4% 2018 11% 2019 10% Portfolio Growth Benchmark¹ (Colombia) MarketProcaps End-user product demand 20% End-user product demand 2019 - 4% 7% 2020 2% 12% 2020 Portfolio of Brands Leveraging Procaps' Innovative Softgel Technologies B2C Rx Drugs OTC Products Diabetes Solutions SPL Source: Procaps, IMS, Close-Up Note: (1) Pharma retail sales (excluding infant milk). IMS, Close-up market reports as of November 2020 FARMA PROCAPS CLINICAL SPECIALTIES VitalCare DIABETRICS 361" EN FUNCIÓN DE LA VIDA Feminine Care Digestive Health Vision Care Blood Clots Personal Protective Equipment (PPE) Gastro-intestinal Selected Therapeutic Areas Skin Care Pain Relief Growth & Development CNS Antibiotics Immunosuppressants Cough & Cold Analgesics Diabetes Solutions 99% of product portfolio is proprietary PROCAPS Skin Care Cardiology Respiratory Oncology Analgesics Urological GROUP VMS * 26

View entire presentation